Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07090148 · ClinicalTrials.gov registry record · Phase 1
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
A Phase 1 study of Recurrent Prostate Cancer and Oligometastatic Prostate Cancer (OMPC), sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT07090148: Recruiting Phase 1 study of Recurrent Prostate Cancer and Oligometastatic Prostate Cancer (OMPC), sponsored by University of Wisconsin, Madison.
NCT07090148 is a Phase 1 study of Recurrent Prostate Cancer and Oligometastatic Prostate Cancer (OMPC) that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 14 participants, below the 138-participant average among 21 other Recurrent Prostate Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07090148, a Phase 1 study of Recurrent Prostate Cancer and Oligometastatic Prostate Cancer (OMPC), is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn whether an experimental vaccine called pTVG-HP ("vaccine" or "DNA vaccine"), combined with a drug called nivolumab can increase the cancer-fighting ability of a person's immune cells. The main question it aims to answer is whether the combination of medicines can get rid of metastatic tumors in participants with non-castrate, recurrent, oligometastatic prostate cancer. Participants will undergo: * Treatment with pTVG-HP * Treatment with Nivolumab * Radiation Therapy
Primary Outcome
Defined as a serum PSA \<0.2 ng/mL at 1 year after prostatectomy
Conditions Studied
Interventions
- DRUG Anti-PD-1 monoclonal antibody
- BIOLOGICAL pTVG-HP DNA vaccine
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2026-03-03 |
| Est. Completion | 2030-10 |
| Phase | Phase 1 |
What NCT07090148 shows while recruiting
NCT07090148 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 138-participant average among 21 other Recurrent Prostate Cancer trials with a reported enrollment target (90% lower).
The record links to 4 conditions, with Recurrent Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Anti-PD-1 monoclonal antibody is the first listed.
NCT07090148 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT07090148 about?
NCT07090148 is a clinical study titled "Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC". The goal of this clinical trial is to learn whether an experimental vaccine called pTVG-HP ("vaccine" or "DNA vaccine"), combined with a drug called nivolumab can increase the cancer-fighting ability of a person's immune cells. The main question it aims to answer is whether the combination of medic...
What is the current status of trial NCT07090148?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2026-03-03. Estimated completion is 2030-10.
What conditions does trial NCT07090148 study?
This clinical trial studies the following conditions: Recurrent Prostate Cancer, Oligometastatic Prostate Cancer (OMPC), Prostate Cancer Patients, Non-castrate Prostate Cancer.
What interventions are being tested in trial NCT07090148?
The interventions under investigation include: Anti-PD-1 monoclonal antibody (DRUG), pTVG-HP DNA vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT07090148?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07090148 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07090148's enrollment target sits among peer trials
14 21st of 21 higher than 1 of 21 other Recurrent Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
RECRUITING · Phase 1
-
Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery
ACTIVE NOT RECRUITING · Phase 1
-
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy